CL2020001307A1 - Formulación. - Google Patents

Formulación.

Info

Publication number
CL2020001307A1
CL2020001307A1 CL2020001307A CL2020001307A CL2020001307A1 CL 2020001307 A1 CL2020001307 A1 CL 2020001307A1 CL 2020001307 A CL2020001307 A CL 2020001307A CL 2020001307 A CL2020001307 A CL 2020001307A CL 2020001307 A1 CL2020001307 A1 CL 2020001307A1
Authority
CL
Chile
Prior art keywords
formulation
polysorbate
glycine
binds
antibody
Prior art date
Application number
CL2020001307A
Other languages
English (en)
Inventor
Sandrine Durran
Andrew Jeffrey Yates
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of CL2020001307A1 publication Critical patent/CL2020001307A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas que comprenden desde un anticuerpo o un fragmento del mismo que se une a IL-17A e IL-17F y una combinación de glicina, tampón de acetato a un pH de 4,6 a 5,5 y polisorbato 80.
CL2020001307A 2017-11-23 2020-05-18 Formulación. CL2020001307A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1719447.3A GB201719447D0 (en) 2017-11-23 2017-11-23 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
CL2020001307A1 true CL2020001307A1 (es) 2020-10-16

Family

ID=60950516

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001307A CL2020001307A1 (es) 2017-11-23 2020-05-18 Formulación.

Country Status (19)

Country Link
US (2) US11857625B2 (es)
EP (1) EP3713602A1 (es)
JP (1) JP6955632B2 (es)
KR (1) KR102767553B1 (es)
CN (1) CN111511399A (es)
AR (1) AR113534A1 (es)
AU (1) AU2018371056B2 (es)
BR (1) BR112020009866A2 (es)
CA (1) CA3082832C (es)
CL (1) CL2020001307A1 (es)
CO (1) CO2020006120A2 (es)
EA (1) EA202091295A1 (es)
GB (1) GB201719447D0 (es)
IL (1) IL274719B2 (es)
MX (1) MX2020004747A (es)
MY (1) MY194682A (es)
RU (1) RU2020120547A (es)
SG (1) SG11202004601YA (es)
WO (1) WO2019101582A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
CN110585430B (zh) * 2019-09-29 2023-09-08 华博生物医药技术（上海）有限公司 一种人源化抗人il-17a单克隆抗体的药物组合物
CN112915201B (zh) 2019-12-06 2023-06-27 珠海市丽珠单抗生物技术有限公司 包含抗il-17抗体的液体制剂
CN113769082A (zh) * 2020-06-10 2021-12-10 上海君实生物医药科技股份有限公司 抗il-17a抗体药物组合物及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019232A2 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
GB0620729D0 (en) * 2006-10-18 2006-11-29 Ucb Sa Biological products
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
BR112012013148A2 (pt) 2009-12-29 2017-03-21 F Hoffmann - La Roche Ag formulação farmacêutica e uso
PH12012501364A1 (en) 2010-01-15 2012-10-22 Amgen K A Inc Antibody formulation and therapeutic regimens
NZ602685A (en) 2010-03-01 2014-10-31 Cytodyn Inc Concentrated protein formulations and uses thereof
SMT202000095T1 (it) * 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
FR2962650B1 (fr) 2010-07-19 2013-04-05 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines concentrees
BR112013011176A2 (pt) * 2010-11-05 2020-09-01 Novartis Ag métodos de tratamento de artrite reumatoide usando antagonistas de il-17
ME02734B (me) * 2011-01-14 2017-10-20 Ucb Biopharma Sprl Antitelo koje vezuje il-17a i il-17f
EA201590061A1 (ru) * 2012-06-21 2015-05-29 Юсб Фарма С.А. Фармацевтическая композиция
WO2016070062A2 (en) * 2014-10-31 2016-05-06 Genentech, Inc. Anti-il-17a and il-17f cross reactive antibody variants and compositions comprising and methods of making and using same
AR103173A1 (es) * 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
RS64263B1 (sr) 2015-08-19 2023-07-31 Astrazeneca Ab Stabilna anti-ifnar1 formulacija
CN116059350A (zh) * 2015-10-27 2023-05-05 Ucb生物制药有限责任公司 使用抗-il-17a/f抗体的治疗方法
GB201522391D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules
EP3443346B1 (en) 2016-04-13 2023-08-30 Medimmune, LLC Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
ES2905917T3 (es) 2016-09-14 2022-04-12 Beijing Hanmi Pharmaceutical Co Ltd Anticuerpo que se une específicamente a IL-17A y fragmento funcional del mismo

Also Published As

Publication number Publication date
CA3082832A1 (en) 2019-05-31
EP3713602A1 (en) 2020-09-30
MY194682A (en) 2022-12-14
US20240123065A1 (en) 2024-04-18
BR112020009866A2 (pt) 2020-11-17
US11857625B2 (en) 2024-01-02
IL274719A (en) 2020-07-30
RU2020120547A3 (es) 2021-12-23
AU2018371056A1 (en) 2020-06-04
RU2020120547A (ru) 2021-12-23
JP6955632B2 (ja) 2021-10-27
CN111511399A (zh) 2020-08-07
CO2020006120A2 (es) 2020-05-29
IL274719B2 (en) 2024-10-01
GB201719447D0 (en) 2018-01-10
JP2021504321A (ja) 2021-02-15
US20210106683A1 (en) 2021-04-15
WO2019101582A1 (en) 2019-05-31
IL274719B1 (en) 2024-06-01
EA202091295A1 (ru) 2020-09-03
CA3082832C (en) 2023-07-18
SG11202004601YA (en) 2020-06-29
AU2018371056B2 (en) 2024-06-20
KR20200090829A (ko) 2020-07-29
MX2020004747A (es) 2020-08-20
AR113534A1 (es) 2020-05-13
KR102767553B1 (ko) 2025-02-12

Similar Documents

Publication Publication Date Title
CL2020001307A1 (es) Formulación.
CO2018008754A2 (es) Composición farmacéutica que comprende constructos de anticuerpo biespecíficos
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
MX2025010757A (es) Formulacion farmaceutica de ph bajo
CL2023001417A1 (es) Composiciones de inhibidores peptídicos del receptor de interleucina - 23.
CU20190015A7 (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden
EP3765522A4 (en) ANTI-CLAUDIN 18.2 ANTIBODIES
CU24568B1 (es) Anticuerpo inhibidor de masp-3
CO2018009533A2 (es) Conjugados de amanitina
JOP20190096A1 (ar) مركبات ببتيد تيروسين-تيروسين الحلقية المقترنة بجسم مضاد كمعدلات لمستقبلات الببتيد العصبي y
MX387451B (es) Formulacion liquida que comprende un compuesto neutralizante de gm-csf.
BR112016026811A2 (pt) formulação de anticorpo
EA202192405A1 (ru) Составы антител против il-36r
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
CO2019002370A2 (es) Anticuerpo que se une específicamente a il-17a y fragmento funcional del mismo
SG11202103670XA (en) Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
SA523450918B1 (ar) أجسام مضادة للنكتين-4 واستخداماتها
BR112021024938A2 (pt) Anticorpos de receptor 1 de peptídeo natriurético e métodos de uso
JOP20200323A1 (ar) طرق لتصنيع تركيبات الأحماض الأمينية
CL2020002459A1 (es) Variantes de anticuerpo c-terminales
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
EA202090945A1 (ru) Анти-msln-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
CO2020015124A2 (es) Anticuerpo anti-tlr7 humano
EP3947466A4 (en) ANTI-HLA-DQ2.5 ANTIBODIES
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека